BPTH
- Bio-Path Holdings, Inc.
()
Overview
Company Summary
Bio-Path Holdings, Inc. is a biotechnology company that specializes in the development of targeted nucleic acid-based therapies for the treatment of cancer. The company focuses on developing innovative drug candidates that are designed to target and disrupt specific genes or proteins that play a role in the progression of cancer.
Bio-Path's flagship drug candidate is called Prexigebersen, which is a liposomal delivery technology designed to inhibit the production of the Grb2 protein. The Grb2 protein is believed to be a key driver of cancer growth and survival and is found at elevated levels in various types of cancer.
Prexigebersen is administered intravenously and works by entering cancer cells and binding to specific RNA molecules, thus preventing the production of Grb2. By inhibiting the production of this protein, Bio-Path aims to disrupt cancer cell signaling pathways and inhibit cancer growth.
Bio-Path is actively conducting clinical trials to evaluate the safety and efficacy of Prexigebersen in different cancers, including acute myeloid leukemia (AML), chronic myeloid leukemia (CML), and triple-negative breast cancer.
In addition to Prexigebersen, Bio-Path is also exploring the development of other potential drug candidates based on its proprietary technology platform. The company's goal is to leverage its expertise in targeted nucleic acid-based therapies to develop effective and safe treatments for cancer patients.
Overall, Bio-Path Holdings, Inc. is dedicated to advancing innovative therapies that have the potential to improve the outcomes and quality of life for individuals battling cancer.